Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

PEG-MGF, or polyethylene glycol-modified mechanogrowth factor, is a peptide that has garnered attention in scientific ...

Progression-free survival for 6 months (PFS6) in recurrent/progressive high-grade meningioma improved more than threefold ...

In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 ...

Thomas H. Sisson, Toby M. Maher, Iyabode O. Ajayi, Jessie E. King, Peter D.R. Higgins, Adam J. Booth, Rommel L. Sagana, Steven K. Huang, Eric S. White, Bethany B ...

Mae founding director Alex Ely puts forward a bold and progressive vision for the future of urban development in the UK – a ...

AKT primarily helps young people aged between 16 and 25 by helping ... Its website has a full listing of all member organisations throughout the UK. Pathway is the UK’s leading homelessness and health ...

A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...